Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Subjects on Stable Buprenorphine/Naloxone Maintenance Therapy.

NCT00828815 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.

NCT NCT00828815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00828815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Subjects on Stable Buprenorphine/Naloxone Maintenance Therapy.
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2009
Completion date
November 30, 2009
Enrollment
22 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, pharmacokinetics